JP2007505108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505108A5 JP2007505108A5 JP2006526096A JP2006526096A JP2007505108A5 JP 2007505108 A5 JP2007505108 A5 JP 2007505108A5 JP 2006526096 A JP2006526096 A JP 2006526096A JP 2006526096 A JP2006526096 A JP 2006526096A JP 2007505108 A5 JP2007505108 A5 JP 2007505108A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight
- active compound
- hcl
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 82
- 150000001875 compounds Chemical class 0.000 claims 25
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 20
- 239000011575 calcium Substances 0.000 claims 20
- 229910052791 calcium Inorganic materials 0.000 claims 20
- QANQWUQOEJZMLL-PKLMIRHRSA-N cinacalcet hydrochloride Chemical compound Cl.N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 QANQWUQOEJZMLL-PKLMIRHRSA-N 0.000 claims 15
- 239000002245 particle Substances 0.000 claims 13
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 10
- 239000008187 granular material Substances 0.000 claims 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 7
- 229920002472 Starch Polymers 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 7
- 239000008107 starch Substances 0.000 claims 7
- 235000019698 starch Nutrition 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 5
- 229960000913 crospovidone Drugs 0.000 claims 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 5
- 229940069328 povidone Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 claims 4
- 229960003315 cinacalcet Drugs 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 238000004090 dissolution Methods 0.000 claims 4
- 238000007922 dissolution test Methods 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- -1 methylenedioxy group Chemical group 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- 239000000853 adhesive Substances 0.000 claims 3
- 230000001070 adhesive effect Effects 0.000 claims 3
- 125000002723 alicyclic group Chemical group 0.000 claims 3
- 238000005469 granulation Methods 0.000 claims 3
- 230000003179 granulation Effects 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 239000012748 slip agent Substances 0.000 claims 3
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 238000009500 colour coating Methods 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 201000005991 hyperphosphatemia Diseases 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 101000939517 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 2 Proteins 0.000 claims 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 102100029643 Ubiquitin carboxyl-terminal hydrolase 2 Human genes 0.000 claims 1
- 230000002092 calcimimetic effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000005029 sieve analysis Methods 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 229940033134 talc Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50221903P | 2003-09-12 | 2003-09-12 | |
| US60/502,219 | 2003-09-12 | ||
| PCT/US2004/026732 WO2005034928A1 (en) | 2003-09-12 | 2004-09-10 | Rapid dissolution formulation of a calcium receptor-active compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012110758A Division JP5849015B2 (ja) | 2003-09-12 | 2012-05-14 | カルシウム受容体−活性化合物の急速溶解処方 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505108A JP2007505108A (ja) | 2007-03-08 |
| JP2007505108A5 true JP2007505108A5 (enExample) | 2007-10-18 |
| JP5026077B2 JP5026077B2 (ja) | 2012-09-12 |
Family
ID=34434844
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526096A Expired - Lifetime JP5026077B2 (ja) | 2003-09-12 | 2004-09-10 | カルシウム受容体−活性化合物の急速溶解処方 |
| JP2012110758A Expired - Lifetime JP5849015B2 (ja) | 2003-09-12 | 2012-05-14 | カルシウム受容体−活性化合物の急速溶解処方 |
| JP2014165378A Expired - Lifetime JP5940120B2 (ja) | 2003-09-12 | 2014-08-15 | カルシウム受容体−活性化合物の急速溶解処方 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012110758A Expired - Lifetime JP5849015B2 (ja) | 2003-09-12 | 2012-05-14 | カルシウム受容体−活性化合物の急速溶解処方 |
| JP2014165378A Expired - Lifetime JP5940120B2 (ja) | 2003-09-12 | 2014-08-15 | カルシウム受容体−活性化合物の急速溶解処方 |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US7829595B2 (enExample) |
| EP (8) | EP3395340B8 (enExample) |
| JP (3) | JP5026077B2 (enExample) |
| KR (1) | KR101332058B1 (enExample) |
| CN (1) | CN1946382B (enExample) |
| AR (1) | AR045637A1 (enExample) |
| AU (1) | AU2004279318C1 (enExample) |
| BR (2) | BR122018013029B1 (enExample) |
| CA (1) | CA2536487C (enExample) |
| CY (5) | CY1119609T1 (enExample) |
| DE (1) | DE19164145T1 (enExample) |
| DK (6) | DK1663182T4 (enExample) |
| EA (1) | EA013425B1 (enExample) |
| ES (7) | ES2401769T5 (enExample) |
| HR (1) | HRP20130114T4 (enExample) |
| HU (5) | HUE035596T2 (enExample) |
| IL (1) | IL173737A (enExample) |
| IS (1) | IS3027B (enExample) |
| MX (1) | MXPA06002616A (enExample) |
| MY (1) | MY142046A (enExample) |
| NO (1) | NO335739B1 (enExample) |
| NZ (1) | NZ545498A (enExample) |
| PL (6) | PL3395339T3 (enExample) |
| PT (6) | PT2821067T (enExample) |
| SG (1) | SG146608A1 (enExample) |
| SI (6) | SI3395338T1 (enExample) |
| TR (4) | TR201910447T4 (enExample) |
| TW (1) | TWI344363B (enExample) |
| WO (1) | WO2005034928A1 (enExample) |
| ZA (1) | ZA200602710B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2401769T5 (es) | 2003-09-12 | 2020-07-01 | Amgen Inc | Formulación de disolución rápida de cinacalcet HCl |
| CN101891680B (zh) | 2004-06-24 | 2014-10-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| US7250533B2 (en) * | 2005-05-16 | 2007-07-31 | Teva Pharmaceutical Industries Ltd | Process for preparing Cinacalcet hydrochloride |
| CA2605764A1 (en) * | 2005-05-23 | 2006-11-30 | Teva Pharmaceutical Industries Ltd. | Amorphous cinacalcet hydrochloride and preparation thereof |
| WO2006127932A2 (en) * | 2005-05-23 | 2006-11-30 | Teva Pharmaceutical Industries Ltd. | Purification of cinacalcet |
| DK1884242T3 (da) | 2005-05-26 | 2013-05-06 | Dainippon Sumitomo Pharma Co | Farmaceutisk sammensætning omfattende lurasidon |
| AU2006285080B2 (en) * | 2005-09-02 | 2012-05-03 | Amgen Inc. | Methods of modulating intestinal fluid balance |
| US7563930B2 (en) * | 2005-11-22 | 2009-07-21 | Teva Pharmaceutical Industries Ltd | Crystal forms of Cinacalcet HCI and processes for their preparation |
| DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
| CA2882048C (en) | 2006-02-03 | 2020-03-24 | Opko Renal, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| US8415501B2 (en) * | 2006-03-23 | 2013-04-09 | Amgen, Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
| JP5027214B2 (ja) * | 2006-04-27 | 2012-09-19 | テバ ファーマシューティカル インダストリーズ リミティド | シナカルセット塩基の調製法 |
| US7393967B2 (en) * | 2006-04-27 | 2008-07-01 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of cinacalcet base |
| HUE037309T2 (hu) | 2006-06-21 | 2018-08-28 | Opko Ireland Global Holdings Ltd | Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer |
| WO2008000422A1 (en) * | 2006-06-27 | 2008-01-03 | Sandoz Ag | Amorphous form of cinacalcet |
| MX2009002335A (es) * | 2006-09-01 | 2009-03-20 | Teva Pharma | Composiciones solidas de un compuesto activo receptor de calcio. |
| WO2008064202A2 (en) * | 2006-11-20 | 2008-05-29 | Dr. Reddy's Labortories, Ltd. | Modified-release formulations of calcium receptor-active compounds |
| US20080146845A1 (en) * | 2006-11-20 | 2008-06-19 | Boaz Gome | Process for preparing Cinacalcet |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| WO2008122010A1 (en) * | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals, Inc. | Pharmaceutical calcimimetics |
| ES2401205T3 (es) | 2007-04-25 | 2013-04-17 | Cytochroma Inc. | Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo |
| WO2009047644A2 (en) | 2007-04-25 | 2009-04-16 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
| EP2170805B1 (en) | 2007-06-21 | 2016-03-16 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
| WO2009025792A2 (en) * | 2007-08-16 | 2009-02-26 | Teva Pharmaceutical Industries Ltd. | Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof |
| EP2300415A2 (en) * | 2008-05-05 | 2011-03-30 | Medichem, S.A. | Process for controlling the particle size of a 3-(trifluoromethyl)phenyl¨-1-aminopropane derivative |
| US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) * | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| WO2010034497A2 (de) | 2008-09-25 | 2010-04-01 | Ratiopharm Gmbh | Kompaktiertes cinacalcet |
| WO2010086129A1 (en) | 2009-01-27 | 2010-08-05 | Rathiopharm Gmbh | Inclusion complex comprising cinacalcet and cyclodextrin |
| KR101727762B1 (ko) | 2009-03-20 | 2017-04-17 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
| US8765676B2 (en) | 2009-05-27 | 2014-07-01 | Leo Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| EP2435400A2 (en) | 2009-05-27 | 2012-04-04 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| EP2314286A1 (de) | 2009-10-21 | 2011-04-27 | Ratiopharm GmbH | Schmelzgranuliertes Cinacalcet |
| CN103037902A (zh) | 2010-03-29 | 2013-04-10 | 赛特克罗公司 | 用于降低甲状旁腺水平的方法和组合物 |
| CN103347517B (zh) | 2010-08-11 | 2018-10-02 | 德雷克塞尔大学 | 治疗帕金森病中运动障碍的d3多巴胺受体激动剂 |
| WO2012071535A2 (en) * | 2010-11-23 | 2012-05-31 | Amgen Inc | Pediatric formulation |
| EP2643298A1 (en) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Substituted cyclopentyl - azines as casr- active compounds |
| RU2013128973A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Соединения, активные в отношении кальций-чувствительных рецепторов |
| US20130244995A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| RU2013128968A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Соединения, активные в отношении кальций-чувствительного рецептора |
| BR112014015003A2 (pt) * | 2011-12-19 | 2019-09-24 | Amgen Inc | composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral |
| EP2804588B1 (en) | 2012-01-17 | 2017-09-06 | Zentiva Saglik Urunleri San. Ve Tic. A.S. | Method for producing cinacalcet compositions for direct tableting |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| CN102885792A (zh) * | 2012-10-12 | 2013-01-23 | 华润赛科药业有限责任公司 | 盐酸西那卡塞的口服固体速释制剂 |
| PL2730279T3 (pl) | 2012-11-09 | 2015-12-31 | K H S Pharma Holding Gmbh | Preparaty cynakalcetu o natychmiastowym uwalnianiu |
| CN105050708A (zh) | 2012-11-14 | 2015-11-11 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| WO2014096277A1 (en) * | 2012-12-21 | 2014-06-26 | Synthon B.V. | Tablet composition comprising cinacalcet hydrochloride |
| SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10016374B2 (en) * | 2013-06-26 | 2018-07-10 | Jubilant Generics Limited | Disintegrant free composition of Cinacalcet |
| EP3116487A1 (en) | 2014-03-14 | 2017-01-18 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical composition of cinacalcet |
| WO2015150944A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| CN104721164B (zh) * | 2015-03-25 | 2017-07-07 | 河北仁合益康药业有限公司 | 一种盐酸西那卡塞薄膜衣片组合物 |
| EP4596045A3 (en) | 2016-03-28 | 2025-10-15 | EirGen Pharma Ltd. | Methods of vitamin d treatment |
| EP3437646A4 (en) | 2016-03-31 | 2019-11-27 | Intercept Pharmaceuticals, Inc. | ORAL PREPARATION WITH EXTRAORDINARY ELABILITY |
| US11331283B2 (en) * | 2017-08-16 | 2022-05-17 | Unichem Laboratories Ltd | Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders |
| US20210030671A1 (en) | 2018-03-30 | 2021-02-04 | Ftf Pharma Private Limited | Liquid dosage forms of cinacalcet or salt thereof |
| US10920483B2 (en) | 2018-10-25 | 2021-02-16 | Mark Mutchnik | Window seal for preventing water penetration |
| RU2750761C2 (ru) * | 2019-09-17 | 2021-07-02 | Общество с ограниченной ответственностью "АМЕДАРТ" | Ядро таблетки, содержащей цинакальцета гидрохлорид |
| AU2021226416A1 (en) * | 2020-02-29 | 2022-09-15 | Zevra Therapeutics, Inc. | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
| CN112546010A (zh) * | 2020-12-02 | 2021-03-26 | 普莱赛思(天津)生命科技有限公司 | 一种肾病药物组合物及其制备方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517179A (en) | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
| IL88150A0 (en) | 1987-11-02 | 1989-06-30 | Merck & Co Inc | Pharmaceutical tablet compositions containing phthalizine acetic acid compounds |
| EP0357815A1 (de) | 1988-09-06 | 1990-03-14 | Siemens Aktiengesellschaft | Schaltbare Konstantstromquelle mit I2L-Gattern |
| AU4664889A (en) | 1988-11-30 | 1990-06-26 | Schering Corporation | Sustained release diltiazem formulation |
| NZ231897A (en) * | 1988-12-30 | 1992-09-25 | Monsanto Co | Dry water-soluble granular composition comprising glyphosate and a liquid surfactant |
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US4931286A (en) | 1989-04-19 | 1990-06-05 | Aqualon Company | High gloss cellulose tablet coating |
| DD299322A5 (de) * | 1989-09-21 | 1992-04-09 | Maschinenfabrik Rieter Ag,Ch | Verfahren und vorrichtung zur feinreinigung von textilfasern |
| US5011068A (en) * | 1989-12-05 | 1991-04-30 | Progressive Tool & Industries Co. | Automotive body framing system |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| DK0724561T3 (da) | 1991-08-23 | 2004-06-28 | Nps Pharma Inc | Calciumreceptoraktive arylalkylaminer |
| ES2256370T3 (es) | 1991-08-23 | 2006-07-16 | Nps Pharmaceuticals, Inc. | Moleculas activas para el receptor de calcio. |
| US6313146B1 (en) * | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| EP0637237B1 (en) | 1993-02-23 | 2004-05-19 | Brigham And Women's Hospital, Inc. | Calcium receptor-active molecules |
| US6210714B1 (en) * | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
| TW398975B (en) * | 1994-07-22 | 2000-07-21 | Lilly Co Eli | Pharmaceutical composition for inhibiting bone loss |
| EP1203761B1 (en) * | 1994-10-21 | 2005-01-19 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
| GB9424766D0 (en) | 1994-12-07 | 1995-02-08 | Wellcome Found | Pharmaceutical composition |
| GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| DE19530575A1 (de) | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz |
| DK0907631T3 (da) | 1996-05-01 | 2003-09-22 | Nps Pharma Inc | Uorganiske ionreceptoraktive forbindelser |
| US5837292A (en) * | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
| TW510896B (en) | 1996-07-08 | 2002-11-21 | Kirin Brewery | Calcium receptor active compounds, the salt or hydrate thereof, and pharmaceutical composition comprising the same |
| DE19637082A1 (de) | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
| TW483881B (en) | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
| IE970588A1 (en) * | 1997-08-01 | 2000-08-23 | Elan Corp Plc | Controlled release pharmaceutical compositions containing tiagabine |
| WO1999009458A1 (de) | 1997-08-13 | 1999-02-25 | OCé PRINTING SYSTEMS GMBH | Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern |
| DE69901938T3 (de) | 1998-03-06 | 2012-08-02 | Aptalis Pharma S.R.L. | Schnell zerfallende tablette |
| US6525084B2 (en) | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
| US6172091B1 (en) | 1998-10-14 | 2001-01-09 | Ortho-Mcneil Pharmaceutical, Inc. | 1,2-Disubstituted cyclopropanes |
| TR200101524T2 (tr) * | 1998-11-23 | 2001-12-21 | Monsanto Co. | Çok konsantre sulu glifosat bileşimleri. |
| UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6447809B1 (en) * | 1999-05-11 | 2002-09-10 | Metagenics, Inc. | Composition for promoting healthy bone structure |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| FR2800735B1 (fr) | 1999-11-09 | 2002-02-01 | Centre Nat Rech Scient | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation |
| EP1239856A1 (en) * | 1999-12-22 | 2002-09-18 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| EP1272181A2 (en) * | 2000-04-13 | 2003-01-08 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
| US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| US6656492B2 (en) * | 2000-06-30 | 2003-12-02 | Yamanouchi Pharmaceutical Co., Ltd. | Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
| JP2002167327A (ja) * | 2000-09-22 | 2002-06-11 | Takeda Chem Ind Ltd | 固形製剤 |
| EP1319409A4 (en) | 2000-09-22 | 2006-05-03 | Takeda Pharmaceutical | SOLID PREPARATIONS |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| IN191028B (enExample) * | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
| JP2005500313A (ja) | 2001-06-22 | 2005-01-06 | ファイザー・プロダクツ・インク | 基材中の低可溶性薬物の固体分散体および溶解度向上性ポリマーを含有する医薬品組成物 |
| EP1321142A1 (en) | 2001-12-21 | 2003-06-25 | Novartis AG | Solid pharmaceutical composition for oral administration of Tegaserod |
| WO2003086343A2 (en) | 2002-04-05 | 2003-10-23 | Cadila Healthcare Limited | Fast disintegrating oral dosage forms |
| US20050147670A1 (en) * | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
| US20040082588A1 (en) | 2002-09-30 | 2004-04-29 | Schering Corporation | Methods for treating disorders of calcium homeostasis |
| GB0230015D0 (en) | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
| ES2401769T5 (es) | 2003-09-12 | 2020-07-01 | Amgen Inc | Formulación de disolución rápida de cinacalcet HCl |
| DE602005025977D1 (de) | 2004-08-23 | 2011-03-03 | Teva Pharma | Kristalline form des ibandronat-natriums und herstellungsverfahren dafür |
| NL1028867C2 (nl) | 2005-04-26 | 2006-10-27 | Xycarb Ceramics B V | Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting. |
| US8922209B2 (en) | 2008-03-11 | 2014-12-30 | The University Of Western Ontario | System and method for magnetic resonance imaging |
-
2004
- 2004-09-10 ES ES04781429T patent/ES2401769T5/es not_active Expired - Lifetime
- 2004-09-10 AR ARP040103266A patent/AR045637A1/es unknown
- 2004-09-10 MY MYPI20043684A patent/MY142046A/en unknown
- 2004-09-10 ES ES18175499T patent/ES2735226T3/es not_active Expired - Lifetime
- 2004-09-10 PL PL18175497T patent/PL3395339T3/pl unknown
- 2004-09-10 PL PL14163366T patent/PL2821067T3/pl unknown
- 2004-09-10 DE DE19164145.5T patent/DE19164145T1/de active Pending
- 2004-09-10 WO PCT/US2004/026732 patent/WO2005034928A1/en not_active Ceased
- 2004-09-10 HU HUE14163366A patent/HUE035596T2/en unknown
- 2004-09-10 PT PT141633669T patent/PT2821067T/pt unknown
- 2004-09-10 SI SI200432475T patent/SI3395338T1/sl unknown
- 2004-09-10 EP EP18175499.5A patent/EP3395340B8/en not_active Revoked
- 2004-09-10 PT PT18175495T patent/PT3395338T/pt unknown
- 2004-09-10 US US10/937,870 patent/US7829595B2/en active Active
- 2004-09-10 PL PL18175499T patent/PL3395340T3/pl unknown
- 2004-09-10 ES ES17185704T patent/ES2734057T3/es not_active Expired - Lifetime
- 2004-09-10 TR TR2019/10447T patent/TR201910447T4/tr unknown
- 2004-09-10 DK DK04781429.8T patent/DK1663182T4/da active
- 2004-09-10 PT PT47814298T patent/PT1663182E/pt unknown
- 2004-09-10 JP JP2006526096A patent/JP5026077B2/ja not_active Expired - Lifetime
- 2004-09-10 ES ES19164145T patent/ES2812198T1/es active Pending
- 2004-09-10 HU HUE18175499 patent/HUE044822T2/hu unknown
- 2004-09-10 EP EP14163366.9A patent/EP2821067B1/en not_active Expired - Lifetime
- 2004-09-10 SI SI200432018T patent/SI1663182T2/sl unknown
- 2004-09-10 SI SI200432473T patent/SI3395339T1/sl unknown
- 2004-09-10 PL PL17185704T patent/PL3260117T3/pl unknown
- 2004-09-10 PT PT18175499T patent/PT3395340T/pt unknown
- 2004-09-10 EP EP18175495.3A patent/EP3395338B1/en not_active Revoked
- 2004-09-10 PT PT17185704T patent/PT3260117T/pt unknown
- 2004-09-10 HU HUE18175497A patent/HUE045411T2/hu unknown
- 2004-09-10 EP EP10014567A patent/EP2316442A1/en not_active Withdrawn
- 2004-09-10 SI SI200432416T patent/SI2821067T1/en unknown
- 2004-09-10 EP EP19164145.5A patent/EP3578175B1/en not_active Revoked
- 2004-09-10 CN CN2004800327959A patent/CN1946382B/zh not_active Expired - Lifetime
- 2004-09-10 PL PL04781429T patent/PL1663182T5/pl unknown
- 2004-09-10 DK DK14163366.9T patent/DK2821067T3/en active
- 2004-09-10 DK DK17185704.8T patent/DK3260117T3/da active
- 2004-09-10 HU HUE18175495 patent/HUE044279T2/hu unknown
- 2004-09-10 HU HUE17185704A patent/HUE043958T2/hu unknown
- 2004-09-10 KR KR1020067003448A patent/KR101332058B1/ko not_active Expired - Lifetime
- 2004-09-10 EP EP17185704.8A patent/EP3260117B8/en not_active Revoked
- 2004-09-10 SI SI200432474T patent/SI3395340T1/sl unknown
- 2004-09-10 DK DK18175495.3T patent/DK3395338T3/da active
- 2004-09-10 TW TW093127508A patent/TWI344363B/zh not_active IP Right Cessation
- 2004-09-10 SI SI200432472T patent/SI3260117T1/sl unknown
- 2004-09-10 DK DK18175499.5T patent/DK3395340T3/da active
- 2004-09-10 AU AU2004279318A patent/AU2004279318C1/en not_active Expired
- 2004-09-10 ES ES18175495T patent/ES2737348T3/es not_active Expired - Lifetime
- 2004-09-10 DK DK18175497.9T patent/DK3395339T3/da active
- 2004-09-10 BR BR122018013029-6A patent/BR122018013029B1/pt active IP Right Grant
- 2004-09-10 MX MXPA06002616A patent/MXPA06002616A/es active IP Right Grant
- 2004-09-10 TR TR2019/10180T patent/TR201910180T4/tr unknown
- 2004-09-10 SG SG200806469-3A patent/SG146608A1/en unknown
- 2004-09-10 TR TR2019/09267T patent/TR201909267T4/tr unknown
- 2004-09-10 ES ES18175497T patent/ES2735216T3/es not_active Expired - Lifetime
- 2004-09-10 HR HRP20130114TT patent/HRP20130114T4/hr unknown
- 2004-09-10 TR TR2019/10177T patent/TR201910177T4/tr unknown
- 2004-09-10 ES ES14163366.9T patent/ES2655435T3/es not_active Expired - Lifetime
- 2004-09-10 CA CA2536487A patent/CA2536487C/en not_active Expired - Lifetime
- 2004-09-10 EA EA200600566A patent/EA013425B1/ru unknown
- 2004-09-10 PT PT18175497T patent/PT3395339T/pt unknown
- 2004-09-10 EP EP04781429.8A patent/EP1663182B2/en not_active Expired - Lifetime
- 2004-09-10 PL PL18175495T patent/PL3395338T3/pl unknown
- 2004-09-10 BR BRPI0414254A patent/BRPI0414254B8/pt active IP Right Grant
- 2004-09-10 NZ NZ545498A patent/NZ545498A/en not_active IP Right Cessation
- 2004-09-10 EP EP18175497.9A patent/EP3395339B8/en not_active Revoked
-
2006
- 2006-02-14 IL IL173737A patent/IL173737A/en active IP Right Grant
- 2006-02-23 IS IS8324A patent/IS3027B/is unknown
- 2006-04-03 ZA ZA200602710A patent/ZA200602710B/en unknown
- 2006-04-11 NO NO20061640A patent/NO335739B1/no unknown
-
2010
- 2010-11-09 US US12/942,646 patent/US9375405B2/en active Active
-
2012
- 2012-05-14 JP JP2012110758A patent/JP5849015B2/ja not_active Expired - Lifetime
-
2014
- 2014-08-15 JP JP2014165378A patent/JP5940120B2/ja not_active Expired - Lifetime
-
2016
- 2016-05-24 US US15/163,356 patent/US20160338975A1/en not_active Abandoned
-
2017
- 2017-11-20 CY CY20171101211T patent/CY1119609T1/el unknown
-
2018
- 2018-04-30 US US15/966,812 patent/US20180243238A1/en not_active Abandoned
- 2018-12-20 US US16/227,882 patent/US20190117592A1/en not_active Abandoned
-
2019
- 2019-06-28 CY CY20191100682T patent/CY1122259T1/el unknown
- 2019-07-10 CY CY20191100734T patent/CY1121812T1/el unknown
- 2019-07-10 CY CY20191100735T patent/CY1121814T1/el unknown
- 2019-07-18 CY CY20191100767T patent/CY1121820T1/el unknown
-
2020
- 2020-03-27 US US16/832,087 patent/US20200222340A1/en not_active Abandoned
- 2020-11-06 US US17/091,798 patent/US20210052518A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2536487A1 (en) | Rapid dissolution formulation of a calcium receptor-active compound | |
| ES2617522T3 (es) | Procedimiento de granulación en seco para fabricar composiciones de comprimidos de metformina y composiciones de los mismos | |
| CA2714112C (en) | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability | |
| HRP20240752T1 (hr) | Postupak za proizvodnju tablete koja sadrži sglt-2 inhibitor i metformin | |
| JP6759390B2 (ja) | トホグリフロジンを含有する固形製剤及びその製造方法 | |
| US20070104785A1 (en) | Tablets of linezolid form iii and processes for their preparation | |
| AU2020358162A1 (en) | Essentially sodium-free effervescent solid pharmaceutical compositions | |
| WO2013091704A1 (en) | Pharmaceutical composition comprising fingolimod | |
| KR20090005513A (ko) | 메트포르민 말론산염, 그의 제조 방법 및 그를 포함하는약제학적 조성물 | |
| CN101939002B (zh) | 与糖醇共微粉化的恩他卡朋药物组合物 | |
| WO2013190151A1 (en) | Pharmaceutical composition comprising fingolimod | |
| JP7336528B2 (ja) | ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物 | |
| TW202312991A (zh) | 氯胺酮衍生物之醫藥組成物及口服劑型 | |
| WO2011036677A2 (en) | Sustained release composition of ranolazine | |
| CN108430462A (zh) | 包括富马酸二甲酯的肠溶包衣口服药物制剂 | |
| JP2017081859A (ja) | テルミサルタン含有錠剤の製造方法 | |
| JP2023532209A5 (enExample) | ||
| TH74395B (th) | สูตรผสมชนิดละลายเร็วของสารประกอบที่ออกฤทธิ์ต่อแคลเซียมรีเซพเตอร์ | |
| TH92453A (th) | สูตรผสมชนิดละลายเร็วของสารประกอบที่ออกฤทธิ์ต่อแคลเซียมรีเซพเตอร์ | |
| WO2006050923A1 (en) | Polymorph form of irbesartan | |
| EP2996681B1 (en) | Pharmaceutical composition comprising fingolimod | |
| US20130273158A1 (en) | Extended release compositions of quetiapine | |
| JP2022086872A (ja) | 酢酸亜鉛含有医薬組成物 | |
| JP2021104974A (ja) | フェブキソスタット製剤 | |
| JP2020147528A (ja) | ダビガトランエテキシラートを含む製剤および安定化方法 |